Posted by Michael Wonder on 05 Jun 2024
Rinvoq (upadacitinib) now available for paediatric patients two years and older with polyarticular juvenile idiopathic arthritis and psoriatic arthritis
4 June 2024 - First indications of Rinvoq (upadacitinib) for paediatric patients two years of age and older.
AbbVie today announced that Rinvoq (upadacitinib) is indicated in the US for the treatment of paediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis as well as psoriatic arthritis, provided they have had an inadequate response or intolerance to one or more tumour necrosis factor blockers. Additionally, a new weight-based oral solution, Rinvoq LQ (upadacitinib), is now available as an option for these paediatric populations.
